Table 5 (abstract P411). Discrimination between patients on infliximab and placebo at week 12
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three
Infliximab mean change (SD) | PBO mean change (SD) | Guyatt’s effect size | SMD | |
|---|---|---|---|---|
ASDAS | 2.4 (1.3) | 0.5 (0.6) | 4.28 | 1.98 |
Physician’s global assessment, 0-10 mm VAS | 5.2 (2.4) | 1.6 (2.2) | 2.34 | 1.56 |
JADAS27 (0-57) | 12.7 (5.9) | 4.3 (5.7) | 2.22 | 1.46 |
JSpADA (0-8) | 2.8 (1.2) | 0.5 (1.4) | 1.98 | 1.73 |
CRP (mg/L) | 21.1 (8.4) | 2.3 (10.9) | 1.93 | 1.90 |
Total enthesitis (0-51) | 8.5 (10.6) | 1.6 (5.0) | 1.71 | 0.85 |
Patient’s global assessment, 0-10 mm VAS | 4.3 (3.8) | 0.8 (2.8) | 1.55 | 1.08 |
BASDAI total (0-10) | 3.3 (3.1) | 0.9 (2.3) | 1.41 | 0.90 |
Active joint count (0-72) | 4.4 (1.7) | 2.6 (4.6) | 0.96 | 0.51 |